吡格列酮对2型糖尿病合并脂肪肝患者血糖、血脂的影响(附38例报告)
出处
《福建医药杂志》
CAS
2009年第4期136-137,共2页
Fujian Medical Journal
参考文献7
-
1高伟,任瑞珍,唐与晓,王秋灵,王玮,孟晓梅.2型糖尿病脂肪肝的筛查及相关因素分析[J].中华糖尿病杂志（1006-6187）,2005,13(2):105-107. 被引量：42
-
2McCullough AJ. Update on nonalcoholic fatty liver disease [J]. J Clin Gastroenterol, 2002, 34 (3).. 255-262.
-
3范建高.非酒精性脂肪肝与代谢综合征[J].国外医学（内分泌学分册）,2002,22(5):284-284. 被引量：23
-
4Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone[J]. Hepatology, 2003, 38 (4) : 1008.
-
5REN MingShan1, HU WenBin1, ZHANG Zhi1, JU ShuangWu1, FAN YuXin2, WANG GongQiang1 and YANG RenMin1Keywords Wilson disease/therapy,copper chelating agents,ATP7B gene,mutations.Copper-chelating therapeutic effect in Wilson disease with different clinical phenotypes and polymorphisms of ATP7B gene[J].World Journal of Gastroenterology,1998,4(4):68-70. 被引量：15
-
6Phillips LS, Grunberger G, Miller E, et al. Once-and twice-daily dosing with roaiglitazone improves glycemic control in patients with type 2 diabetes [J]. Diabetes Care, 2001, 24 (2): 308-315.
-
7金菊英,余叶蓉.噻唑烷二酮类药物对2型糖尿病大血管病变的影响及其机制[J].中国糖尿病杂志,2003,11(4):285-287. 被引量：30
二级参考文献22
-
1[1]Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor γ-ligands inhibit development of atherosclerosis in LDL receptor-dificient mice. J Clin Invest,2000,106:523-531.
-
2[2]Minamikava J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab,1998,83:1818-1820.
-
3[3]Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care,2001,24:683-689.
-
4[4]Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type Ⅱdiabetes. Diabetes,1996,45:1661-1669.
-
5[5]Yang C, Chang TJ, Chang JC, et al. Rosiglitazone(BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway. Diabetes,2001,50:2598-2602.
-
6[6]Oakes ND, Thalén PG, Jacinto SM, et al. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes,2001,50:1158-1165.
-
7[7]Murakami K, Tobe K, Ide T, et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma:effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats . Diabetes,1998,47:1841-1847.
-
8[8]Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: A potential mechanism of insulin sensitization. Endocrinology,2002,143:998-1007.
-
9[9]Walker AB, Chattington PD, Buckingham RE, et al. The thiazolidinedione rosiglitazone(BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes,1999,48:1448-1453.
-
10[10]Nordt TK, Peter K, Bode C, et al. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab,2000,85:1563-1568.
共引文献101
-
1陈国生,丁宏建,许震宁.老年人脂肪肝与代谢综合征的相关性分析[J].浙江预防医学,2009,21(3):27-28. 被引量：1
-
2Guo-Qing Hou~1 Xiu-Ling Liang~2 Rong Chen~2 Li-Wen Tang~3 Ying Wang~2 Ping-Yi Xu~2 Ying-Ru Zhang~2 Cui-Hua Ou~2 1 Department of Neurology.Guangzhou First Municipal People’s Hospital,Guangzhou Medical College,Guangzhou 510180,Guangdong Province.China2 Department of Neurology.First Affiliated Hospital.Sun Yat-Sen University of Medical Sciences.Guangzhou 510080.Guangdong Province.China3 Department of Pharmacology,University of Kentucky.Lexington,KY 40506.USA.Copper transportion of WD protein in hepatocytes from Wilson disease patients in vitro[J].World Journal of Gastroenterology,2001,7(6):846-851. 被引量：4
-
3康爱英,王国庆,张建阁.中老年脂肪肝患病情况及相关因素分析[J].第四军医大学学报,2004,25(20). 被引量：4
-
4龚循俊,张健.马来酸罗格列酮的临床应用[J].中国煤炭工业医学杂志,2004,7(11):1019-1020. 被引量：1
-
5徐方江,于凤玲,于凤泉,顾全霞,李群.吡格列酮治疗早期糖尿病肾病微量白蛋白尿及C反应蛋白水平观察[J].重庆医学,2005,34(1):56-57. 被引量：5
-
6夏碧文.吡格列酮对2型糖尿病疗效和血脂影响的研究[J].热带医学杂志,2005,5(5):713-714. 被引量：3
-
7王俊宏,宋基中,刘艳晓,董书会,田勇,吴利军,李素娜,马平均.罗格列酮在糖调节受损合并非酒精性脂肪肝病中的应用体会[J].中国医师杂志,2006,8(1):122-123. 被引量：3
-
8余季文,晏莲英,赵玉琴.2型糖尿病伴发脂肪肝的临床特点[J].安徽医药,2006,10(6):445-446. 被引量：1
-
9宋淑萍.2型糖尿病脂肪肝与脂代谢、胰岛素抵抗的关系[J].天津医药,2006,34(6):415-416. 被引量：4
-
10曾斌,史静,谢晓敏.2型糖尿病合并非酒精性脂肪肝与胰岛素抵抗和瘦素的关系[J].临床荟萃,2006,21(14):1021-1022.
-
1程红岩,章韵.肝脏单结节样脂肪浸润的影像诊断[J].中华放射学杂志,1994,28(5):346-347. 被引量：1
-
2汤庆娅.合理减重:防治非酒精性脂肪肝的关键[J].中国社区医师,2010(30):11-11.
-
3肝炎患者不可滥用保肝药[J].健康,1994,0(4):39-40.
-
4Eguchi Y.,Eguchi T.,Mizuta T.,陈云茹.内脏脂肪堆积与胰岛素抵抗是非酒精性脂肪性肝病的重要发病因素[J].世界核心医学期刊文摘（胃肠病学分册）,2006,0(11):40-40. 被引量：5
-
5陈克敏,林晓珠,柴维敏.脂肪性肝病的影像学检查[J].诊断学理论与实践,2014,13(4):444-445. 被引量：1
-
6何远流,李鸿.非均匀性肝脂肪浸润的超声分型诊断[J].临床医学影像杂志,1995,6(1):50-51. 被引量：3
-
7汤善宏,杨德会,曾维政,吴晓玲,王钊,周晓蕾,李红永,陈洪超,范泉水,蒋明德.酒精性肝硬化合并局限性肝脂肪浸润病变误诊为肝癌1例报告并文献复习[J].临床肝胆病杂志,2015,31(3):438-440. 被引量：1
-
8段丽丽,曹惠萍,马吉玉.非均匀性肝脂肪浸润的实时超声诊断[J].山东医药,1999,39(11):20-20.
-
9何江英,刘志国,秦恩强,洪炜,刘佳.华支睾吸虫病1例报告[J].传染病信息,2007,20(1):62-63. 被引量：3
-
10刘姿含.预防儿童脂肪肝 预约美好未来[J].家庭医学（上半月）,2015,0(8):26-26.
